Compare J B Hunt Transport Services Inc (JBHT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? J B Hunt Transport Services Inc trades at $232.16 (market cap $21.52B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: J B Hunt Transport Services Inc is far larger — about 22.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 46 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JBHT | MRVI | |
|---|---|---|
Market Cap | $21.52B | $972.90M |
Volume | 994,790 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $298.41 | $9.00 |
52-Week Low | $138.83 | $2.83 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $22.66B | $1.08B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $232.16, up 1.69% today, with a bearish technical signal but strong fundamental profitability. Recent earnings have consistently beaten expectations, with Q3 2026 results due October 15, 2026. The company maintains solid margins, with a net income margin of 5.31% and ROE of 18.45%, though revenue has declined from 2022 peaks. Cash flow from operations remains healthy at $1.68 billion for 2025.
Analyst consensus is bullish with a $287.93 price target, but near-term risks include rising costs pressuring Q3 earnings and multiple law firm investigations into potential securities claims. The stock offers upside if execution improves, but investors face headwinds from fuel expenses and legal overhangs.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
